Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CLL-1 CAR-T cells
- Development stage
- Preclinical
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-CLL-1 CAR-T cells are a type of chimeric antigen receptor (CAR) T-cell therapy designed to treat acute myeloid leukemia (AML). These engineered T cells target C-type lectin-like molecule-1 (CLL-1), also known as CLEC12A or CD371, an antigen frequently expressed on AML cells but largely absent on normal hematopoietic stem cells. The CAR-T cells are genetically modified to express a CAR that recognizes and binds to CLL-1 on cancer cells, leading to their destruction. This therapy involves collecting a patient's T cells, genetically modifying them in vitro, expanding them, and then infusing them back into the patient.
- Other names
- CAR-T cellsCAR-T细胞
02
Targets
CLEC12A
Beyond the preview
Go deeper on anti-CLL-1 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CLL-1 CAR-T cells.